arrow
D

Daniel Wetterskog

University of London
H指数:27
被引数:3,333

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer

复发性肿瘤内异质性是转移性前列腺癌的标志

2026-06-190
OAAI
Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study

联合ctDNA和血清PSA动态监测转移性前列腺癌开始一线治疗: 一项前瞻性国家队列研究

2026-05-150
OAAI
Tumor proliferation associates with greater sensitivity to androgen receptor pathway inhibition in metastatic prostate cancer

肿瘤增殖与转移性前列腺癌中对雄激素受体通路抑制的更高敏感性相关

2026-05-150
OA
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers

肿瘤转录组范围表达分类器预测晚期前列腺癌的治疗敏感性

Cell
IF42.5
2025-08-260
OAAI
External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol

基于数字病理学的多模态人工智能衍生预后模型在开始长期雄激素剥夺治疗的晚期前列腺癌患者中的外部验证:STAMPEDE平台方案的四项Ⅲ期随机对照试验的回顾性附加生物标志物研究

2025-06-010
OAAI
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer. the STAMPEDE Phase 3 Randomized Clinical Trial

血浆AR改变及强化激素治疗前列腺癌的时机:STAMPEDE III期随机临床试验

2025-02-270
PRE
Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial

进展性前列腺癌患者开始使用多西他赛联合或不联合恩扎卢替尼时的液体活检:PRESIDE 3b期试验的生物标志物研究

2025-02-011
OAAI
Open-label, multicentre randomised trial of Radium223-docetaxel versus docetaxel-Radium223 sequence in metastatic castration resistant prostate cancer (mCRPC) with prospective biomarker evaluation (RAPSON study)

开放标签、多中心随机试验,比较镭223-多西他赛与多西他赛-镭223序贯疗法在转移性去势抵抗性前列腺癌(mCRPC)中的应用(并前瞻性评估生物标志物)(RAPSON研究)

2024-09-010
PRE
Dynamics of plasma tumour DNA and copy number alterations in advanced metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel: A prospective biomarker trial
2023-10-010
OA
Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial
2023-10-010
PRE
Copy number architectures define treatment-mediated selection of lethal prostate cancer clones
2023-08-102
OAAI
Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay
2022-05-279
OAAI
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients
2021-10-139
PREAI
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
2021-09-0673
OAAI
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study
2021-07-014
PRE